The present invention provides a new use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate salt thereof: wherein: G is selected from a group consisting of: phenyl, pyridyl, benzothiazolyl, indazolyl； p is an integer ranging from 0 to 5； R1 is independently selected from a group consisting of: halogen, hydroxyl, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl； or corresponds to a group R5； R2 is hydrogen or C1-4alkyl； R3I s C1-4alkyl； R4 is hydrogen, or a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl； R5 is a moiety selected from the group consisting of: isoxazolyl, -CH2-N-pyrrolyl, 1,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl, 2-pyrrolidinonyl, and such a group is optionally substituted by one or two substituents selected from: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl； and when R1 is chlorine and p is 1, such R1 is not present in the ortho position with respect to the linking bond to the rest of the molecule； and when R1 corresponds to R5, p is 1； in the manufacture of a medicament for the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome； and in the manufacture of a medicament for the treatment of premature ejaculation.본 발명은 신체형 장애, 예컨대 신체 변형 장애 또는 건강염려증, 신경성 과식증, 신경성 거식증, 폭식증, 성도착증 및 비-성도착적 성적 중독, 시덴함 무도병, 사경, 자폐증, 튜렛 증후군을 비롯한 운동 장애, 및 조루증의 치료를 위한 의약의 제조에 있어서, 화학식 I의 화합물, 또는 그의 제약상 허용되는 염 또는 용매화물의 새로운 용도를 제공한다.<；화학식 I>；식 중,G는 페닐, 피리딜, 벤조티아졸릴, 인다졸릴로 이루어진 군으로부터 선택되고；p는 정수 0 내지 5이고；R1은 할로겐, 히드록실, 시아노, C
